Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Total Valuation
United Therapeutics has a market cap or net worth of $13.82B. The enterprise value is $11.74B.
Market Cap$13.82B
Enterprise Value$11.74B
Share Statistics
United Therapeutics has 45,106,625 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,106,625
Owned by Insiders7.07%
Owned by Institutions1.46%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 16.14%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)16.14%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee2.20M
Profits Per Employee915.79K
Employee Count1,305
Asset Turnover0.39
Inventory Turnover1.96
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio12.2
PS Ratio0.00
PB Ratio1.96
Price to Fair Value2.47
Price to FCF11.91
Price to Operating Cash Flow9.47
PEG Ratio4.43
Income Statement
In the last 12 months, United Therapeutics had revenue of 2.88B and earned 1.20B in profits. Earnings per share was 26.44.
Revenue2.88B
Gross Profit2.57B
Operating Income1.38B
Pretax Income1.54B
Net Income1.20B
EBITDA1.65B
Earnings Per Share (EPS)26.44
Cash Flow
In the last 12 months, operating cash flow was 1.41B and capital expenditures -283.20M, giving a free cash flow of 1.13B billion.
Operating Cash Flow1.41B
Free Cash Flow1.13B
Free Cash Flow per Share25.02
Dividends & Yields
United Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change-9.41%
50-Day Moving Average300.43
200-Day Moving Average332.99
Relative Strength Index (RSI)59.28
Average Volume (3m)515.89K
Important Dates
United Therapeutics upcoming earnings date is Jul 30, 2025, Before Open (Confirmed).
Last Earnings DateApr 30, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date―
Financial Position
United Therapeutics as a current ratio of 5.25, with Debt / Equity ratio of 2.94%
Current Ratio5.25
Quick Ratio5.03
Debt to Market Cap0.00
Net Debt to EBITDA-0.84
Interest Coverage Ratio32.10
Taxes
In the past 12 months, United Therapeutics has paid 343.90M in taxes.
Income Tax343.90M
Effective Tax Rate0.22
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 8.80, with an EV/FCF ratio of 13.47.
EV to Sales5.06
EV to EBITDA8.80
EV to Free Cash Flow13.47
EV to Operating Cash Flow10.96
Balance Sheet
United Therapeutics has $3.32B in cash and marketable securities with $200.00M in debt, giving a net cash position of -$3.12B billion.
Cash & Marketable Securities$3.32B
Total Debt$200.00M
Net Cash-$3.12B
Net Cash Per Share-$69.20
Tangible Book Value Per Share$140.09
Margins
Gross margin is 89.00%, with operating margin of 47.86%, and net profit margin of 41.53%.
Gross Margin89.00%
Operating Margin47.86%
Pretax Margin53.49%
Net Profit Margin41.53%
EBITDA Margin57.50%
EBIT Margin54.98%
Analyst Forecast
The average price target for United Therapeutics is $383.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$383.00
Price Target Upside25.00% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast19.85%
EPS Growth Forecast21.16%